Advances and Progress in Chagas Disease Drug Discovery

Title:Advances and Progress in Chagas Disease Drug Discovery

Volume: 16 Issue: 20

Author(s): Leonardo G. Ferreira, Marcelo T. de Oliveira and Adriano D. Andricopulo

Affiliation:

Keywords: American trypanosomiasis, Cruzain, CYP51, Trypanosoma cruzi, Neglected tropical diseases, Inhibitors.

Abstract: Chagas disease represents a serious burden for millions of people worldwide. Transmitted by the protozoan parasite Trypanosoma cruzi, this neglected tropical disease causes more than 10,000 deaths each year and is the main cause of heart failure in Latin America, where it is endemic. Although most cases are concentrated in Latin American countries, Chagas disease has been increasingly reported in non-endemic regions, where the low level of public awareness on the subject contributes to the growing prevalence of the disease. The available medicines are characterized by several safety and efficacy drawbacks that prevent millions of people, particularly those with advanced disease, from receiving adequate treatment. This urgent need has stimulated the emergence of diverse initiatives dedicated to the research and development (R&D) of novel therapeutic agents for Chagas disease. Public-private partnerships have been responsible for a significant increase in the investments in R&D programs and major advancements have been achieved over the past ten years. A number of collaborative projects have been leveraged by this organizational model, which privileges sharing of data, expertise, and resources between research institutions and pharmaceutical companies. Among the current strategies employed by these consortia, target-based and phenotypic screenings have achieved the most promising results. This article provides an overview on the current status and recent advances in Chagas disease drug discovery.

Cite this article as:

G. Ferreira Leonardo, T. de Oliveira Marcelo and D. Andricopulo Adriano, Advances and Progress in Chagas Disease Drug Discovery, Current Topics in Medicinal Chemistry 2016; 16 (20) . https://dx.doi.org/10.2174/1568026616666160413124902